NAS:CTNM (USA)
Â
Class A Common Stock
$
15.46
-0.21 (-1.37%)
10:10 PM EST
Business Description
Contineum Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US21217B1008
Share Class Description:
CTNM: Class A Common StockTotal Employee Number:
51Description
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 35.42 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.7 | |||||
3-Year EPS without NRI Growth Rate | -19.8 | |||||
3-Year FCF Growth Rate | -20.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.29 | |||||
9-Day RSI | 61.91 | |||||
14-Day RSI | 58.99 | |||||
3-1 Month Momentum % | 27.85 | |||||
6-1 Month Momentum % | 14.94 | |||||
12-1 Month Momentum % | 177.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.3 | |||||
Shareholder Yield % | -0.55 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -27.89 | |||||
ROA % | -26.33 | |||||
ROIC % | -592.76 | |||||
3-Year ROIIC % | -625.37 | |||||
ROC (Joel Greenblatt) % | -916.62 | |||||
ROCE % | -31.21 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.32 | |||||
Price-to-Tangible-Book | 2.31 | |||||
EV-to-EBIT | -5.12 | |||||
EV-to-EBITDA | -5.15 | |||||
EV-to-Forward-Revenue | 11.59 | |||||
EV-to-FCF | -6.35 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 2.46 | |||||
Earnings Yield (Greenblatt) % | -19.53 | |||||
FCF Yield % | -9.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Contineum Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.73 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 88.99 | ||
| 14-Day RSI | 58.99 | ||
| 14-Day ATR ($) | 1.097501 | ||
| 20-Day SMA ($) | 14.63175 | ||
| 12-1 Month Momentum % | 177.8 | ||
| 52-Week Range ($) | 5.07 - 16.91 | ||
| Shares Outstanding (Mil) | 37.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Contineum Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Contineum Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 90 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 4 days | ||
| General meeting for 2026 | 2026-06-26 08:00 | 13.36 (+3.81%) | ||
| Guidance call for 2026 | 2026-06-09 13:20 | 11.53 (-1.11%) | ||
| Guidance call for 2026 | 2026-05-19 15:35 | 12.86 (-4.39%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 14.15 (+7.20%) | ||
| Guidance call for 2026 | 2026-03-11 14:20 | 13.41 (-1.90%) | ||
| Annual report for 2025 | 2026-03-05 | 14.86 (+4.57%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 14.86 (+4.57%) | ||
| Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference | 2025-12-03 13:20 | 10.49 (-3.94%) |
Show
Entries
Contineum Therapeutics Inc Frequently Asked Questions
What is Contineum Therapeutics Inc(CTNM)'s stock price today?
The current price of CTNM is $15.46. The 52 week high of CTNM is $16.91 and 52 week low is $5.07.
When is next earnings date of Contineum Therapeutics Inc(CTNM)?
The next earnings date of Contineum Therapeutics Inc(CTNM) is 2026-08-05 Est..
Does Contineum Therapeutics Inc(CTNM) pay dividends? If so, how much?
Contineum Therapeutics Inc(CTNM) does not pay dividend.
Guru Commentaries on NAS:CTNM
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers